



# Hereditary disorders of peroxisomal metabolism



# Peroxisomes



single membrane organelles

from less than 100 to more than 1000 per eukaryotic cell

more than 50 enzymes

*beta-oxidation of very long chain fatty acids*


*biosynthesis of ether phospholipids (plasmalogens)*

*biosynthesis of bile acids*



*biosynthesis of isoprene compounds*

*production of hydrogen peroxide, catalase*

# Main metabolic pathways in peroxisomes



# Biogenesis of peroxisomes



# Biogenesis of peroxisomes

Synthesis of matrix proteins on **free ribosomes in cytoplasm**

## **Receptor-mediated import of proteins** into organelle

C-terminal peroxisome targeting sequence PTS1  
((S/A/C)-(K/R/H)-L-COOH)

PTS1 is recognized by a cytosolic receptor PEX5

Few matrix proteins are targeted by N-terminal PTS2 ((R/  
K)(L/V/I)<sub>5</sub>(Q/H)(L/A)

Membrane proteins – also synthesized on free ribosomes and imported

# PEX genes encode peroxins

Peroxisins are necessary for peroxisome biogenesis

PTS1, PTS2, other cytosolic and integral membrane proteins  
e.g. PEX5 is a receptor for PTS1

Involved in the import of peroxisomal matrix and membrane proteins

15 known genes in humans

# Disorders of peroxisome biogenesis

## Complex developmental and metabolic phenotypes

Most severe phenotype: Zellweger syndrome

Milder : Infantile Refsum disease

**Peroxisomal ghosts** – aberrant peroxisomal structures,  
“empty” peroxisomal membranes

Severe disruption of **peroxisomal functions**

# Zellweger syndrome

Described by dr.Hans Zellweger in 1961

## Cerebrohepatorenal syndrome

Incidence cca 1:50 000 births

Peroxisomal proteins were not properly compartmentalized  
("Peroxisomal ghosts")

Other milder disorders of peroxisomal biogenesis were described

**Neonatal ALD**

**Infantile Refsum disease**

Rhizomelic chondrodystrophia punctata



# Zellweger syndrome

Facial dysmorphism: full forehead, hypoplastic supraorbital ridges, large anterior fontanelle, epicanthal folds, broad nasal bridge,

Ocular abnormalities: cataracts, glaucoma, corneal clouding, pigmentary retinopathy, optic nerve dysplasia

Severe hypotonia, weakness, seizures

Abnormal punctate calcifications in the patella and epiphyses of the long bones

Renal cysts

# Zellweger syndrome



Punctate calcifications („calcific stippling“) in the patella



# Neonatal adrenoleukodystrophy, infantile Refsum disease

Peroxisomes may be present

Dysmorphic features are less striking or even absent

Often longer survival, psychomotor retardation

Demyelination, polymicrogyria, atrophic adrenals

Sensorineural hearing loss

Pigment retinopathy


# Neonatal adrenoleukodystrophy, infantile refsum disease



A



B




C



D

# **X-linked adrenoleukodystrophy**

# Intracellular oxidation of C26:0



# Peroxisomal oxidation of fatty acids


Different proteins – not enzymes involved in mitochondrial  
BOX, different regulation

4 enzymatic reactions catalyzed by 3 enzymes :

1. acyl-CoA oxidase,
2. multifunctional protein (enoylCoA hydratase, hydroxyacyl-CoA dehydrogenase),
3. 3-oxoacyl-CoA-thiolase

FAD-linked acylCoA oxidases : enzyme bound FADH<sub>2</sub> is directly reoxidized by molecular O<sub>2</sub> to produce H<sub>2</sub>O<sub>2</sub>

-----  
„Activation“ of VLCFA by thioesterification to CoA  
fatty acid:CoA ligases (Acyl CoA synthetases)






# X-linked adrenoleukodystrophy

X-linked disease, ALDP: Xq28

ABC half-transporter ALDP: functions as a homodimer and accepts acyl-CoA esters



**Cerebral X-ALD** - a rapidly progressive intensely inflammatory myelinopathy that may involve autoimmune mechanisms.

**Adrenomyeloneuropathy** is a noninflammatory distal axonopathy involving mainly the spinal cord long tracts and to a lesser extent peripheral nerves. “Atrophy” of spinal cord


Addison disease

Asymptomatic

Heterozygous females


Biochemical defect at the level of long-chain acyl-CoA synthetase - elevated levels of very-long chain fatty acids

## MRI-pattern of X-ALD



# AGE OF ONSET OF NEUROLOGICAL SYMPTOMS OF CEREBRAL FORMS OF ADRENOLEUKODYSTROPHY AND ADRENO MYELONEUROPATHY

CEREBRAL  
ALD                      AMN  
- - - - -                      \_\_\_\_\_



# Lorenzo's oil

A 4 : 1 mixture of glyceryl trioleate and glyceryl trierucate


Normalizes the levels of VLCFA in the plasma of X-ALD patients.

Possibly partially effective in prevention of progression in patients without neurological symptoms/adrenomyeloneuropathy


Developed by Augusto Odone



Hugo Moser



Erucic acid



Oleic acid



# Alopecia in adrenomyeloneuropathy

